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Abstract: The viral gene delivery of optogenetic actuators to the surviving inner retina has been
proposed as a strategy for restoring vision in advanced retinal degeneration. We investigated the
safety of ectopic expression of human rod opsin (hRHO), and two channelrhodopsins (enhanced
sensitivity CoChR-3M and red-shifted ReaChR) by viral gene delivery in ON bipolar cells of the
mouse retina. Adult Grm6Cre mice were bred to be retinally degenerate or non-retinally degenerate
(homozygous and heterozygous for the rd1Pde6b mutation, respectively) and intravitreally injected
with recombinant adeno-associated virus AAV2/2(quad Y-F) serotype containing a double-floxed
inverted transgene comprising one of the opsins of interest under a CMV promoter. None of the
opsins investigated caused changes in retinal thickness; induced apoptosis in the retina or in transgene
expressing cells; or reduced expression of PKCα (a specific bipolar cell marker). No increase in retinal
inflammation at the level of gene expression (IBA1/AIF1) was found within the treated mice compared
to controls. The expression of hRHO, CoChR or ReaChR under a strong constitutive promoter in
retinal ON bipolar cells following intravitreal delivery via AAV2 does not cause either gross changes
in retinal health, or have a measurable impact on the survival of targeted cells.
Keywords: optogenetics; vision restoration; ON bipolar cells; rodopsin; channelrhodopsin
1. Introduction
Optogenetic strategies show promise as therapeutic approaches to restore photosensi-
tivity in advanced retinal degeneration [1–7]. In conditions such as retinitis pigmentosa,
neurons within the inner retina survive photoreceptor degeneration, making them suitable
candidates for the ectopic expression of photosensitive proteins. An important consid-
eration in the future development of these therapies is their safety. In particular, it is
important to determine the impact of the therapeutic expression of optogenetic actuators
on the cells in which they are expressed, and the wider retinal structure. On the one hand,
there is the theoretical possibility that the ectopically expressed photosensitive protein
may itself be toxic, or induce toxicity through means such as chronic activation [8]. On the
other, toxicity may arise from other aspects associated with viral gene therapy, shown with
recent evidence suggesting that the viral delivery of transgenes, including non-selective
promoters, can be toxic in the retina [9].
Here, we set out to test the safety of the viral expression of human rod opsin (hRHO)
and two channelrhodopsins; a Chloromonas oogama channelrhodopsin mutant (CoChR-3M)
and red-shifted channelrhodopsin variant (ReaChR) in ON bipolar cells of the mouse retina.
Multiple opsins have been shown to restore a functional basis of vision when ectopically
expressed within the remaining intact retina of rodent models of retinal degeneration,
including microbial light-gated ion channels and pumps [7], and naturally occurring and
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synthetic light-gated G-protein coupled receptors [2,6,10,11]. For this study, we firstly chose
to investigate human rod opsin [3,12], as it is a native human protein and possesses advan-
tages in terms of photosensitivity over standard microbial opsins [13,14]. To accompany
the hRHO dataset, we also investigated two channelrhodopsins with enhanced therapeutic
potential: CoChR-3M, which has enhanced light sensitivity [15]; and a red-activatable
channelrhodopsin, ReaChR, which possesses improved light tissue penetrating properties
compared to the normal shorter wavelength counterparts [16]. In all cases, we targeted
opsin expression to ON bipolar cells, as several studies have reported that this strategy
provides the best outcome in terms of visual restoration [4,6,12,17,18].
The delivery method of choice for recent optogenetic therapies are adeno associated
viruses (AAVs), which are now applied in a clinical setting for retinal gene therapy [19].
Here, we employed a capsid mutant (quad Y-F) of the AAV2 serotype, which has been
shown to provide good transduction of bipolar cells following intravitreal injection in the
degenerate mouse retina [20,21]. In order to restrict the expression to ON bipolar cells, we
employed a mouse line (Grm6cre) in which Cre recombinase is expressed in these cells [22].
The GRM6 gene is responsible for encoding the metabotropic glutamate receptor mGluR6,
which is localised within ON bipolar cells [23,24]. In this way, we hoped to achieve ON
bipolar cell-specific transgene expression using Cre-dependent activation of a transgene
comprising an opsin under the control of a strong ubiquitous promoter (CMV). This had
several advantages over the alternative of employing an ON bipolar cell-specific promoter
(e.g., grm6-SV40) in the viral transgene [17]. Firstly, it provided greater confidence that
the transgene expression was restricted to the target cells. Secondly, it allowed us to use a
strong, ubiquitous promoter for our transgene construct that has previously been shown to
enhance toxicity, thus maximising the potential for our study to reveal safety concerns.
2. Results
2.1. Expression of Human Rod Opsin in ON Bipolar Cells Using the Grm6cre Mouse
Intravitreal injections of DIO rod opsin–mCherry AAV2 to rd1/rd1;Grm6Cre mice re-
sulted in transgene expression across the retina (Figure 1A). Examination of the retinal
sections revealed mCherry expression in the outer portion of the inner nuclear layer
(INL) in the degenerate retinas, as expected for ON bipolar cell targeting. Further to
this, immunocytochemical staining for the ON bipolar cell marker PKCα revealed strong
co-localisation with the mCherry reporter (Figure 1B–E), and that mCherry-expressing
cells also co-localised with the rod opsin expression (Figure 1F–I). We also included the
non-degenerate mice (rd1/+;Grm6Cre) in our study to ensure that any transgene-induced
change in morphology was not masked by ongoing degeneration. This pattern of mCherry
expression was recapitulated in the non-degenerate (rd1/+;Grm6Cre) retina (Figure 1J–P).
These data confirm that the combination of a ubiquitous promoter in the DIO system with
the Grm6Cre mouse represents an effective strategy for driving transgene expression in
mouse ON bipolar cells.
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Figure 1. Characterisation of a Grm6Cre Rd1 mouse treated with human rod opsin. (A) A representa-
tive wholemount retinal image of a Grm6Cre/+ rd1/rd1 mouse following an intravitreal injection of
AAV2(4Y-F)-CMV-DIO-hRHO-T2A-mCherry displaying widespread transduction of the mCherry
reporter. (B–E) Cross section of a rod opsin-treated retina of a Grm6Cr/+e rd1/rd1 mouse displaying
mCherry co-localisation within PKCα-expressing bipolar cells. (B) DAPI (in blue), (C) mCherry (in
red), (D) PKCα (in green), (E) merge of B, C and D. (F–I) Cross section of a rod opsin-treated Grm6Cre
rd1/rd1 mouse displaying mCherry co-localisation with human rod opsin (hRHO). (F) DAPI (in blue),
(G) mCherry (in red), (H) rod opsin (in green), (I) = merge of F, G and H. (J–L) A cross section of a
rod opsin-treated retina of a Grm6Cre rd1/+ mouse. (F) DAPI (in blue), (G) mCherry (in red), (H) =
merge of (F,G). (M–P) Cross section of a rod opsin-treated Grm6Cre rd1/+ mouse displaying mCherry
co-localisation with PKCα. (M) DAPI (in blue), (N) mCherry (in red), (O) PKCα (in green), (P) merge
of M, N and O. Scale bars = 100 µm. ONL = outer nuclear layer; INL = inner nuclear layer; GCL =
ganglion cell layer.
2.2. Gross Retinal Anatomy Is Not Impaired by Viral Delivery of Rod Opsin to ON Bipolar Cells
As a first step to determine whether rod opsin treatment is detrimental to retinal
integrity, we applied optical coherence tomography (OCT) to measure the retinal thickness
in vivo. To maximise our ability to detect changes in retinal integrity, we established a
longitudinal study in which we could assess changes in the retinal thickness over time in
groups of injected and non-treated control mice, as well as in both retinally degenerate and
non-degenerate mice. The mice were injected at 2 months of age (after a baseline OCT) and
OCT measures were made at 3, 5 and 8 months old (1, 3 and 6 months post-treatment).
We found no evidence of retinal thinning associated with the gene therapy in ei-
ther retinally degenerate or intact animals at any of the timepoints tested. As expected,
both the inner nuclear layer (INL) and, to a more dramatic extent, the total retinal thick-
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ness were reduced in the retinally degenerate animals. The total retinal thickness de-
creased over time in both genotypes (two-way RM-ANOVA main effect of time (F = 3.767,
p = 0.0394) for rd1/rd1 and (F = 7.598, p = 0.001) for rd1/+) (Figure 2A,E), but there was
no impact of treatment (main effect of treatment (F = 3.007, p = 0.1049) for rd1/rd1 and
(F = 0.1895, p = 0.6704) for rd1/+) and interaction (F = 1.209, p = 0.3182) for rd1/rd1 and
(F = 2.156, p = 0.1087) for rd1/+). A similar pattern was observed in INL thickness, with
a significant decrease found over time in both genotypes (two-way mixed ANOVA main
effect of time (F = 5.287, p = 0.0037) for rd1/rd1 and (F = 9.842, p < 0.0001) for rd1/+), also
with no impact of treatment (main effect of treatment (F = 1.451, p = 0.2498) for rd1/rd1
and (F = 1.458, p = 0.2448) for rd1/+ and interaction (F = 0.8602, p = 0.4699) for rd1/rd1 and
(F = 2.365, p = 0.0826) for rd1/+) (Figure 2B,F). Representative images of the retinal thickness
assessments from the OCTs are shown from a pre-injection timepoint (2 months old) and
the last assessment (8 months old) in retinally degenerate (Figure 2C,D, respectively) and
non retinally degenerate (Figure 2G,H, respectively) mice. Within these images, the blue
lines represent the borders used to measure the total retinal thickness, and the yellow lines
represent the borders for the INL measurement.
Figure 2. Longitudinal study of retinal thickness in a Grm6Cre Rd1 mouse treated with human rod
opsin. Total retinal thickness (A) and INL thickness (B) in rod opsin-treated and control mice within
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degenerate retinas (control n = 8, treated n = 7). Representative OCTs of retinae pre-treatment at 2 months
old (C) and post-rod opsin treatment at 8 months old (D) from rd1/rd1. Longitudinal study of total retinal
thickness (E) and INL thickness (F) in rod opsin-treated and control mice within non-degenerate rd1/+
retinas (control n = 8, treated n = 10). Representative OCTs of retinae pre-treatment at 2 months old (C)
and post-rod opsin treatment at 8 months old (D) from rd1/rd1 and at 2 months old (G) and post-rod
opsin treatment at 8 months old (H) in rd1/+. No significant difference was found between the control
and treated groups in either group; however, time was shown to have a significant effect on INL thickness
(p = 0.0037 (rd1/rd1), p < 0.0001 (rd1/+)) and total retinal thickness (p = 0.0175 (rd1/rd1), p = 0.0004 (rd1/+))
(two-way mixed ANOVA, repeated measures, Bonferonni multiple).
2.3. ON Bipolar Cell Survival Is Not Impacted by Viral Delivery of Rod Opsin
Next, we asked whether the ON bipolar cell population in particular was impacted by
our viral gene delivery of rod opsin in to rd1/rd1;Grm6Cre mice. Our first approach was to
assess the level of expression of an ON bipolar cell marker (PKCa) at 3, 6 and 10 months
post-injection with the viral vector (5, 8 and 12 months of age). Prior to collecting tissue for
this study, we measured OCTs to provide a context for our findings. Consistent with the
results of our longitudinal study, we found no evidence of INL thinning induced by the
treatment (Figure 3B, two-way mixed ANOVA main effect of time (F = 0.3579, p = 0.7011),
treatment (F = 0.9100, p = 0.3450) and interaction (F = 0.7847, p = 0.4622)). Turning to PKCa
expression, qPCR from the whole retinas revealed equivalent levels of this ON bipolar
cell marker in the treated and untreated groups across the time points tested (Figure 3A,
two-way mixed ANOVA main effect of time (F = 0.1562, p = 0.8564), treatment (F = 0.4298,
p = 0.5199) and interaction (F = 0.3066, p = 0.7395)).
As a final test of toxicity, we took the other eye from this group of animals and sub-
jected it to TUNEL staining to reveal apoptotic cells. An exploration of the retinal sections
revealed that the levels of TUNEL staining were very low across all three investigated
time points in our treated groups, and significantly lower than in a positive control section
treated with DNAse (Figure 3G). This impression was confirmed by the quantification of
TUNEL staining (positive pixel count) (Figure 3C). Across the INL, the positive pixel count
was always low at < 0.4%, but this did increase with age, and time was shown to have a
significant effect (two-way mixed ANOVA, F = 4.583, p = 0.0256). Importantly, however, the
levels of apoptosis were not impacted by treatment (two-way mixed ANOVA main effect
of treatment (F = 0.0002, p = 0.9885) and interaction (F = 0.0165, p = 0.9836)). A possibility
is that TUNEL staining could be higher in the fraction of INL neurones expressing the
transgene. In practice, this proved not to be the case. Thus, out of 453 mCherry stained
cells (from all ages), we found only 2 that had TUNEL-positive nuclei.
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Figure 3. Toxicity study on a cellular level of rod opsin-treated Grm6Cre rd1/rd1 retinas. (A) PKCα
expression in rod opsin-treated and control rd1/rd1 mice. (B) INL thickness of rod opsin-treated
and non-treated control rd1/rd1 mice (C) Levels of apoptosis (TUNEL positivity) within the INL of
rod opsin-treated and control rd1/rd1 mice. (D–F) Representative images of mCherry and TUNEL
co-localisation at 5 months of age (D), 8 months of age (E), 12 months of age (F) and a DNase-treated
positive control (G). No effect of the treatment was found on the INL thickness (two-way mixed
ANOVA p > 0.05); or on the PKCa expression (two-way mixed ANOVA p > 0.05). Across the INL, the
positive pixel count was always low (< 0.4%), but this did increase with age, and time was shown
to have a significant effect (two-way mixed ANOVA, p < 0.05). Importantly, however, the levels of
apoptosis were not impacted by treatment (two-way ANOVA, p > 0.05).
2.4. Expression of Channelrhodopsin Variants Does Not Impact Gross Retinal Anatomy or Bipolar
Cell Number
Next, we applied a similar approach to investigate the safety of two channelrhodopsins
with promising characteristics for vision restoration, a Chloromonas oogama more light-
sensitive channelrhodopsin mutant (CoChR-3M), and a red-sensitive channelrhodopsin
(ReaChR). The viral gene delivery of these opsins with an mCherry reporter (vector maps
shown in Supplementary Figure S1) in rd1/rd1;Grm6Cre mice resulted in the widespread
distribution of mCherry expression throughout the wholemounts (Figure 4A–C), compa-
rable to that of rod opsin-treated mice (Figure 1A). Co-localisation with PKCa confirmed
transgene expression in ON bipolar cells within the retinal cross sections (Figure 4D–G).
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Some mCherry positive cells were found to be PKCa-negative, but as these are located in
INL, they may be cone ON bipolar cells [17].
Figure 4. Characterisation of a Grm6Cre rd1 mouse treated with channelrhodopsins: ReaChR and CoChR-
3M. (A,B) Representative retinal wholemount images of Grm6Cre rd1/rd1 mice following intravitreal
injection of ReaChR in (A) and CoChR-3M in (B), displaying widespread transduction of the mCherry
reporter. (C(i–iv),D(i–iv)) Retinal cross sections of Grm6Cre rd1/rd1 mice following intravitreal injection
of ReaChR in (C) and CoChR-3M in (B) displaying mCherry co-localisation within PKCα-expressing
bipolar cells: ReaChR in (C) and CoChR-3M in (D). (C(i),D(i)) mCherry (in red); (C(ii),D(ii)) PKCα (in
green) and (C(iii),D(iii)) DAPI (in blue), (C(iv),D(iv)) represent merge of corresponding images. ONL =
outer nuclear layer; INL = inner nuclear layer; GCL = ganglion cell layer.
We undertook a longitudinal investigation into retinal thickness using OCT in cohorts
of rd1/rd1;Grm6Cre mice expressing either one of the two channelrhodopsins or, for compar-
ison, rod opsin or non-injected control mice. The mice were injected between 60 and 80
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days and OCTs were recorded at 1, 3, 6 and 9 months post-treatment (3, 5, 8 and 11 months
of age). There was a significant decrease in the INL thickness observed over time in all
mice (two-way RM-ANOVA main effect of time F = 61.89, p < 0.001), but no impact of any
of the treatments was found (two-way RM-ANOVA main effect of treatment (F = 1.307,
p = 0.2918) or interaction (F = 0.6868, p = 0.7189)) (Figure 5A).
To identify the possible impacts on bipolar cell survival and retinal inflammation,
a further cohort of animals was injected with a virus and scheduled for qPCR analysis
of PKCa and IBA1/AIF1 expression at 4 months post-treatment. The OCT measurements
at 2 and 4 months after treatment confirmed that there was no impact from any of the
treatments (two-way mixed ANOVA main effect of treatment (F = 0.5861, p = 0.6260)
or interaction (F = 0.7401, p = 0.5314)) (Figure 5B). At 4 months, the qPCR analysis of
mCherry expression (normalised to GADPH) revealed comparable levels of expression
for the three transgenes compared to the control (Figure 5C; the Kruskal–Wallis test with
Dunn’s multiple comparisons correction, p = 0.9789). The analysis of the expression of
PKCa and IBA1/AIF1 found no difference between any of the treatments compared to
controls (Figure 5D,E; the Kruskal–Wallis test with Dunn’s multiple comparisons correction,
p = 0.2051). These results suggest that there was no change in the rod ON bipolar cell number
or retinal inflammation at the level of gene IBA1/AIF1 expression due to the opsin treatments.
Figure 5. Toxicity study of opsin-treated Grm6Cre rd1/rd1 retinae. (A) Longitudinal study and
(B) non-longitudinal study of INL thickness in rod opsin; ReaChR- and CoChR-3M-treated and
control mice. (C) mCherry relative expression in rod opsin; ReaChR- and CoChR-3M-treated and
non-injected control mice. (D) PKCα relative expression and (E) IBA1/AIF1 relative expression in
rod opsin; ReaChR- and CoChR-3M-treated and control mice. There was a significant decrease
in the INL thickness observed over time in all mice (two-way RM-ANOVA main effect of time
p < 0.001), but no impact of any of the treatments was found (p > 0.05). Analysis of the expression of
PKCa and IBA1/AIF1 found no difference between any of the treatments compared to controls (the
Kruskal–Wallis test with Dunn’s multiple comparisons correction, p > 0.05).
3. Discussion
Our study did not reveal significant safety concerns for optogenetic therapies involv-
ing hRHO or the two channelrhodopsins investigated (CoChR-3M, and ReaChR) expressed
in ON bipolar cells. We combined a transgenic mouse (Grm6Cre rd1/rd1) with intravitreal
injection of a recombinant AAV2(4Y-F) vector providing Cre-dependent expression of the
opsin of interest under a strong constitutive promoter (CMV) to introduce expression into
ON bipolar cells. We showed that this strategy produced transgene expression in the target
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cells, and that no evidence of detrimental effects on retinal integrity linked to the transgene
was found using a variety of approaches.
OCT measurements of retinal thickness are commonly used in human and animal studies
to track retinal degeneration. This method has the ability to reveal very small changes in retinal
thickness [25] and can reveal both swelling and thinning of the retina associated with many
disease states. Importantly, because this method is non-invasive, it can be applied in a repeated
measures design to track changes in individual mice over time, enhancing statistical power.
We applied this approach here to explore the long-term effects of the optogenetic therapy. We
found no change in thickness associated with treatment in either degenerate or intact retinas,
which suggests that there was no effect on the retinal tissue that would be masked by ongoing
degeneration. This was true whether we measured the whole retina, or concentrated on the
region targeted for expression (the inner nuclear layer). We also found no changes in the INL
thickness of mice treated with CoChR-3M and ReaChR.
The OCT data thus confirm that at a gross level, the retinas in rd1/rd1;Grm6Cre mice
are not affected, even up to 9 months after treatment, compared to controls. A legitimate
concern is that toxicity in the cells actually expressing the transgene may not be apparent
in such measures of the whole retinal population. We addressed that possibility first
by looking for changes in the expression of an ON bipolar cell-specific marker. Such an
approach has been used to reveal ganglion cell degeneration following oxygen/glucose
deprivation (by measuring the ganglion cell marker THY1) [26]. In principle, this should
also be applicable to the assessment of bipolar cells with the use of PKCa (a specific marker
of rod bipolar cells (RBCs) [27,28]). Previous studies have shown a decrease in the PKCa
expression at the protein level as a result of NMDA excitotoxicity, which was correlated to
a decrease in the health/functional state of RBCs [29]. Here, we found no evidence of a
decrease in PKCa expression at the RNA level in hRHO-, CoChR-3M-, or ReaChR-treated
mice. Further to this, we also investigated IBA1/AIF1 expression as a means of assessing any
potential changes in retinal inflammation due to treatment [30]. No increases in IBA1/AIF1
expression were found with any treatment when assessed as individual treatments vs. control,
or as a grouped assessment (all treatments grouped vs. control), indicating that the treatment
and delivery method induced no significant increase in retinal inflammation at the level of
IBA1 gene expression compared to the non-treated controls. Future studies will be needed to
further assess potential inflammation by investigating the protein expression of AIF1 and glial
fibrillary acidic protein (GFAP), as well as activation of Müller cells staining.
As viral transduction can never successfully target all ON bipolar cells across the whole
retina, we finally looked for evidence of degeneration specifically in those neurons that
actually expressed the transgene. Our approach was to use TUNEL staining at early, mid
and late time points after injection to determine whether there was evidence of apoptosis
in transgene-expressing neurons. Consistent with our other findings, TUNEL staining was
very low in the retinas of treated animals (and not significantly enhanced compared to
controls). Moreover, there was no indication of enhanced TUNEL staining in the INL as a
whole, nor in the hRHO cells expressing the transgene.
The data presented here provide reassurance that a therapy based upon rod opsin or
investigated channelrhodopsins need not have substantial safety concerns. One issue that
we have not addressed is the possibility that the long-term exposure to the high light levels
required for the optogenetic activation of microbial opsins might have detrimental effects.
Our study, however, did include rod opsin and Co-ChR-3M, which are both activated
at moderate light intensities and would have experienced optogenetic activation. The
mice treated with these opsins displayed no evidence of retinal degeneration, indicating
that moderate light intensity and optogenetic activation of the likes of hRHO and Co-
ChR-3M induce no additional retinal degeneration in comparison to opsins that will not
have seen optogenetic activation, such as ReaChR. A more significant limitation of our
study is that, in mice, we cannot replicate the very long treatment times (many years) that
would be required for a human therapy. Nevertheless, within the constraints of a rodent
study, we have tried to replicate long-term expression (up to 9 months post-injection) and
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found no evidence of retinal degeneration due to the opsin expression. An important
finding from this study is that we found no link between the ubiquitous promoter (CMV)
and bipolar cell death. This issue was highlighted in a recent study that showed that
the promoter used for transgene expression can have a substantial impact on toxicity in
ocular gene therapy [9]. We found no evidence of bipolar cell-linked toxicity with the
use of this ubiquitous promoter. Future studies will be needed to address any potential




All animal experiments were conducted in accordance with the UK Animals (Scientific
Procedures) Act (1986) and approved by the UK Home Office under the animal licence
PP3176367. Adult Grm6Cre mice [22] were a kind gift from Robert Duvoisin (Oregon Health
Sciences) and kept on a mixed background of C57BL/6-C3H/HeH, where they were bred to be
non-retinally degenerate (rd1/+) or retinally degenerate (rd1/rd1). The mice were intravitreally
injected in both eyes with 2.5 µL of AAV2(4Y-F) viral vectors containing one of the opsins
(Vectorbuilder, vector maps shown in Supplementary Figure S1) between the ages of 60 and 80
days. The mice were culled via cervical dislocation at designated endpoints, in the case of the
non-longitudinal samples at time points 3, 5, 8 and 12 months of age for the hRHO study, and
at 6 months of age for the channelrhodopsin study. In the case of the longitudinal study, all
eyes were retrieved at 8 months of age for the hRHO study.
4.2. Immunohistochemistry
The eyes were collected and fixed in 4% paraformaldehyde (PFA) in PBS overnight.
After fixing, the eyes were then placed into 30% sucrose in PBS overnight for cryopreser-
vation. The eyes were embedded in OCT and frozen on dry ice before being sectioned at
20 µM thickness.
For mCherry staining, sections were blocked in blocking solution (5% donkey serum in
PBS with 0.1% Triton X) before the application of rabbit polyclonal anti-mCherry antibody
(Kerafast, USA) to the slides at 1:400 in blocking solution at 4 ◦C overnight. After washing,
donkey anti-rabbit Alexa 546 (Invitrogen, 1:500) was applied to the slides for 2 h at room
temperature. Further washing then took place before the addition of either monoclonal rabbit
anti-PKCa (Abcam, 1:500), or monoclonal mouse anti-rhodopsin (4D2) (Abcam, 1:500) was
applied to the slides in blocking solution overnight at 4 ◦C. After washing, donkey anti-rabbit
or mouse Alexa 488 (Abcam, 1:500) was applied to the slides for 2 h at room temperature. The
slides were mounted with ProLong Gold Antifade with DAPI (ThermoFisher, UK) and allowed
to dry overnight. For mCherry and PKCa co-staining, following the staining for mCherry, the
slides were washed for 2 h longer and then blocked again in blocking solution (5% donkey
serum in PBS with 0.1% Triton X). Further washing then took place before monoclonal rabbit
anti-PKCa (Abcam, 1:400) was applied to the slides in blocking solution overnight at 4 ◦C.
After washing, donkey anti-rabbit Alexa 647 (Invitrogen, 1:500) was applied to the slides for
2 h at room temperature. The slides were mounted with ProLong Gold Antifade with DAPI
(ThermoFisher) and allowed to dry overnight.
Apoptotic cells were detected utilising the Click IT Plus TUNEL assay tagged with
Alexa Flour 647 (ThermoFisher), according to the manufacturer’s instructions.
The retinal wholemounts were dissected after the eyes’ fixation in 4% PFA overnight.
The retinal wholemounts were then permeabilised in 1% Triton X in PBS for 1 h at room
temperature, and then put into blocking solution that contained 10% donkey serum in
1% Triton X in PBS for 3 h at room temperature. The primary antibody rabbit polyclonal
anti-mCherry antibody (Kerafast) was applied to the retinas at 1:400 in blocking solution
at 4 ◦C overnight. The retinas were then washed in 0.2% Triton X in PBS and incubated
with secondary antibody donkey anti-rabbit Alexa 546 (Invitrogen, 1:500), which was
applied in blocking solution overnight at 4 ◦C. After sufficient washing of the retinas in
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0.2% Triton X in PBS, they were mounted with fluorescent mounting media (ProLong Gold,
ThermoFisher).
Images of the retinal cross sections with rod opsin therapy were collected on a Zeiss
Axioimager D2 upright microscope using a 20 x/0.5 EC Plan-Neofluar objective and were
captured using a Coolsnap HQ2 camera (Photometrics) through Micromanager software
v1.4.23. Specific band pass filter sets for DAPI, FITC and Texas red were used to prevent
bleed through from one channel to the next. Images of the retinal wholemounts were
collected on a Leica M205 FA upright stereomicroscope using a 5 x/0.50 PlanAPO LWD
objective at the equivalent of 10 × magnification and were captured using a DFC 365FX
(Leica) camera through LAS AF v3.1.0.8587 software (Leica). Specific band pass filter sets
for mCherry were used to prevent bleed through from one channel to the next. Images of
the retinal cross sections from the channelrhodopsin therapies were collected on a Leica
SP8x AOBS inverted confocal using a 40 x/0.85 HCX PL APO objective. The confocal
settings were as follows: pinhole (1 airy unit), scan speed (600Hz bidirectional), format
(1024 × 1024). The images were collected using (hybrid) detectors with the following
detection mirror settings: DAPI 360–400 nm; Red 560–600 nm; and Cy5 640–690 nm, using
the UV and white light lasers. When acquiring 3D optical stacks, the confocal software
was used to determine the optimal number of Z sections. Only the maximum intensity
projections of these 3D stacks are shown in the results.
The assessment of TUNEL staining was done in ImageJ and conducted using the
following method: A DNase positive control sample was run alongside each group and
the threshold of analysis set to 100%, whereby the number of TUNEL-stained pixels within
the inner nuclear layer (INL) is equal to the number of pixels of DAPI-stained nuclei. This
threshold was then applied to the treated and untreated samples and a percentage of
apoptotic cell pixels to cell nuclei pixels was calculated.
4.3. PCR
The eyes were collected at designated endpoints and the retinae isolated and stored
in RNAlater (ThermoFisher) until the RNA was collected using the RNeasy Mini Kit (Qi-
agen, UK), and cDNA produced using the Tetro cDNA synthesis kit (Bioline, UK). The
gene expression was assessed using the LightCycler 480 (Roche, UK) with the LightCycler
480 SYBR Green Mastermix (Roche, UK). The gene expression for the hRHO studies was
normalised via a relative expression method, whereby the hRHO was divided by the geo-
metric mean of the three housekeeping genes ARP (acidic ribosomal phosphoprotein P0),
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and PSMB2 (proteasome subunit
beta type-2) [32]. For the channelrhodopsins and rod opsin comparison study, the gene
expression was normalised to GAPDH. The primers were produced by Sigma (see Table 1).

















4.4. Optical Coherence Tomography
The mice were anaesthetised using isoflurane and the retinal thickness assessed within
the central region of the retina ventral to the optic nerve using the Phoenix Micron 4 system
(Phoenix Technology Group, CA, USA). The retinal thickness was calculated using InSight
(Phoenix Technology Group, CA, USA) version 2.0.5940. As part of the inclusion criteria for
the OCT analysis, qPCR was conducted on all samples at the end of the study to confirm
transgene expression within the treated samples and absence in the control samples.
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